Inhibitory effects of Rubi Fructus extracts on hepatic steatosis development in high-fat diet-induced obese mice

Nam,Mi  Kyung; Choi,Hye  Ran; Cho,Jin  Sook; Cho,Soo Min; Ha,Ki  Chan; Kim,Tae-Hyeon; Ryu,Hee-Young; Lee,Young-Ik

doi:10.3892/mmr.2014.2398

Inhibitory effects of Rubi Fructus extracts on hepatic steatosis development in high-fat diet-induced obese mice

Authors:
- Mi Kyung Nam
- Hye Ran Choi
- Jin Sook Cho
- Soo Min Cho
- Ki Chan Ha
- Tae-Hyeon Kim
- Hee-Young Ryu
- Young-Ik Lee
View Affiliations

Affiliations: Industrial Bioresource Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-606, Republic of Korea, Lee's Biotech Co., Daejeon 305-806, Republic of Korea, Healthcare Claims and Management Incorp., Jeonju, Chonbuk 949-14, Republic of Korea, Department of Gastroenterology, Wonkwang University School of Medicine, Iksan, Chonbuk 500-711, Republic of Korea
Published online on: July 21, 2014 https://doi.org/10.3892/mmr.2014.2398
Pages: 1821-1827

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was performed to investigate the potential effects of the unripened dried fruit of Rubus coreanus Miq., Rubi Fructus (RF), on hepatic steatosis and lipid metabolism in mice fed with a high‑fat diet (HFD) known to induce obesity and hyperlipidaemia. Rubi Fructus extract (RFex) fed mice demonstrated a reduced body weight and adipose tissue weight. RFex fed mice also demonstrated decreased aminotransferase levels, lipid contents [triglyceride (TG), total cholesterol (TC) and low‑density lipoprotein‑cholesterol (LDL‑C)], leptin content and increased high‑density lipoprotein‑cholesterol (HDL‑C) contents in the plasma. These effects were accompanied by a decreased expression of lipogenic genes, including sterol regulatory element binding protein‑1c, liver X receptor, fatty acid synthase (FAS), acetyl‑CoA carboxylase, cluster of differentiation 36, lipoprotein lipase and decreased lipogenic enzyme FAS and 3‑hydroxy‑3 methylglutamyl coenzyme reductase enzyme activities, while elevating carnitine palmitoyltrasferase‑1 activity. Based on these results, the present study hypothesized that the inhibitory effect on hepatic steatosis of RFex is the result of the suppression of lipid synthesis in mice fed with HFD, suggesting that RFex may be beneficial in preventing hepatic steatosis and liver lipotoxicity.

View Figures

View References

1	Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N and Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 37:917–923. 2003. View Article : Google Scholar : PubMed/NCBI
2	Schreuder TC, Verwer BJ, van Nieuwkerk CM and Mulder CJ: Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol. 14:2474–2486. 2008. View Article : Google Scholar : PubMed/NCBI
3	Kotronen A and Yki-Järvinen H: Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 28:27–38. 2008. View Article : Google Scholar : PubMed/NCBI
4	Edmison J and McCullough AJ: Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis. 11:75–104. 2007. View Article : Google Scholar : PubMed/NCBI
5	Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G and Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 50:1844–1850. 2001. View Article : Google Scholar : PubMed/NCBI
6	Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM and Martinez-Chantar ML: Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol. 41:969–976. 2009. View Article : Google Scholar : PubMed/NCBI
7	Nepokroeff CM, Lakshmanan MR and Porter JW: Fatty-acid synthase from rat liver. Methods Enzymol. 35:37–44. 1975. View Article : Google Scholar : PubMed/NCBI
8	Targher G, Bertolini I, Rodella S, Zoppini G, Lippi G, Day C and Muggeo M: Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 51:444–450. 2008. View Article : Google Scholar
9	Unger RH, Clark GO, Scherer PE and Orci L: Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta. 1801:209–214. 2010. View Article : Google Scholar : PubMed/NCBI
10	Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L and Colin P: Ursodeoxycholic acid for treatment of nonalcoholic steatosis steatohepatitis: results of a randomized trial. Hepatology. 39:770–778. 2004. View Article : Google Scholar : PubMed/NCBI
11	Sgro C and Escousse A: Side effects of fibrates (except liver and muscle). Therapie. 46:351–354. 1991.(In French).
12	Cha HW, Park MS and Park KM: Physiological activities of Rubus coreanus Miquel. Korean J Food Sci Tech. 33:409–415. 2001.
13	Yang HM, Oh SM, Lim SS, Shin HK, Oh YS and Kim JK: Antiinflammatory activities of Rubus coreanus depend on the degree of fruit ripening. Phytother Res. 22:102–107. 2008.
14	Oh MS, Yang WM, Chang MS, Park W, Kim do R, Lee HK, Kim WN and Park SK: Effect of Rubus coreanus on sperm parameters and cAMP responsive element modulator (CREM) expression in rat testes. J Ethnopharmacol. 114:463–467. 2007.
15	Lee MW: Phenolic compounds from the leaves of Rubus coreanus. Yakhak Hoeji. 39:200–204. 1995.
16	Perry LM: Medicinal plants of east and southeast Asia, attributed properties and uses. MIT press; Cambridge, MA: pp. 346–356. 1980
17	Sohn DW, Kim HY, Kim SD, Lee EJ, Kim HS, Kim JK, Hwang SY, Cho YH and Kim SW: Elevation of intracavernous pressure and NO-cGMP activity by a new herbal formula in penile tissues of spontaneous hypertensive male rats. J Ethnopharmacol. 120:176–180. 2008. View Article : Google Scholar : PubMed/NCBI
18	Lee YI, Choi SK, Yang JY, Cho JS and Kim TH: Hepatoprotective activities of Rubus coreanus depends on the degree of ripening. Natural Product Sciences. 15:156–161. 2009.
19	Lee YI, Whang KE, Cho JS, Ahn BM, Lee SB, Dong MS and Kim TH: Rubus coreanus extract attenuates acetaminophen induced hepatotoxicity; involvement of cytochrome P450 3A4. Biomol Ther. 17:455–460. 2009. View Article : Google Scholar
20	Hwang JM, Cho JS, Kim TH and Lee YI: Ellagic acid protects hepatocytes from damage by inhibiting mitochondrial production of reactive oxygen species. Biomed Pharmacother. 64:264–270. 2010. View Article : Google Scholar : PubMed/NCBI
21	Kang EH, Kown TY, Oh GT, Park WF, Park SI, Park SK and Lee YI: The flavonoid ellagic acid from a medicinal herb inhibits host immune tolerance induced by the hepatitis B virus-e antigen. Antiviral Res. 72:100–106. 2006. View Article : Google Scholar : PubMed/NCBI
22	Kaul A and Khanduja KL: Plant polyphenols inhibit benzoyl peroxide-induced superoxide anion radical production and diacylglyceride formation in murine peritoneal macrophages. Nutr Cancer. 35:207–211. 1999. View Article : Google Scholar
23	Folch J, Lees M and Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 226:497–509. 1957.
24	Hulcher FH and Oleson WH: Simplified spectrophotometric assay for microsomal 3-hydroxy-3-methylglutaryl CoA reductase by measurement of coenzyme A. J Lipid Res. 14:625–631. 1973.
25	Markwell MA, McGroarty EJ, Bieber LL and Tolbert NE: The subcellular distribution of carnitine acyltransferases in mammalian liver and kidney. J Biol Chem. 248:3426–3432. 1973.PubMed/NCBI
26	Angulo P: Nonalcoholic fatty liver disease. N Eng J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
27	Dixon JB, Bhathal PS and O’Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 121:91–100. 2001. View Article : Google Scholar : PubMed/NCBI
28	Zelcer N and Tontonoz P: Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest. 116:607–614. 2006. View Article : Google Scholar : PubMed/NCBI
29	Horton JD, Goldstein JL and Brown MS: SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 109:1125–1131. 2002. View Article : Google Scholar : PubMed/NCBI
30	Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ and Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI
31	Liu H, Li J, Zhao W, Bao L, Song X, Xia Y, Wang X, Zhang C, Wang X, Yao X and Li M: Fatty acid synthase inhibitors from Geum japonicum Thunb. var chinense. Chem Biodivers. 6:402–410. 2009. View Article : Google Scholar
32	Meyer AS, Heinonen M and Frankel EN: Antioxidant interactions of catechin, cyanidin, caffeic acid, quercetin and ellagic acid on human LDL oxidation. Food Chem. 61:71–75. 1998. View Article : Google Scholar
33	Yu YM, Chang WC, Wu CH and Chiang SY: Reduction of oxidative stress and apoptosis in hyperlipidemic rabbits by ellagic acid. J Nutr Biochem. 16:675–681. 2005. View Article : Google Scholar : PubMed/NCBI